The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial
2007 ◽
Vol 92
(4)
◽
pp. 1305-1310
◽
2017 ◽
Vol 2
(3)
◽
pp. 46
◽
2005 ◽
Vol 60
(1)
◽
pp. 41-43
◽
2014 ◽
Vol 16
(3)
◽
pp. 319-325
◽
2017 ◽
Vol 33
(2)
◽
pp. 211-220
◽
2019 ◽
Vol 34
(3)
◽
pp. 572-572
◽
2009 ◽
Vol 28
(1)
◽
pp. 42-48
◽